<DOC>
	<DOCNO>NCT01656525</DOCNO>
	<brief_summary>Objective study evaluate safety , tolerability , pharmacokinetics preliminary pharmacodynamic effect multiple dos Gantenerumab subject mild moderate AD .</brief_summary>
	<brief_title>A Multiple-dose Study Gantenerumab Japanese Alzheimer &amp; Apos ; Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis probable AD dementia , base NINCDS/ADRDA criterion Meet DSMIV criterion Dementia Alzheimer type MMSE score : 16 26 etc . Meet exclusion criterion MRI screening . A history significant neurodegenerative disease dementia Alzheimer 's disease . etc .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>